Maribavir (MBV) versus Investigator-Assigned Therapy (IAT) for Refractory Cytomegalovirus (CMV) Infection (with or without Resistance) in Solid Organ Transplant (SOT) Recipients: Subgroup Safety Analysis of a Phase 3 Study.
AMERICAN JOURNAL OF TRANSPLANTATION（2022）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要